Show simple item record

dc.contributor.advisorHaque, Fahim Kabir Monjurul
dc.contributor.authorRitu, Sanjida Sultana
dc.contributor.authorDihan, Alaya Ferdous
dc.date.accessioned2022-01-23T05:09:45Z
dc.date.available2022-01-23T05:09:45Z
dc.date.copyright2021
dc.date.issued2021-11
dc.identifier.otherID 17126012
dc.identifier.otherID 17126044
dc.identifier.urihttp://hdl.handle.net/10361/15965
dc.descriptionThis thesis is submitted in partial fulfilment of the requirements for the degree of Bachelor of Science in Microbiology, 2021.en_US
dc.descriptionCatalogued from PDF version of thesis.
dc.descriptionIncludes bibliographical references (pages 16-21).
dc.description.abstractMalaria is an ancient vector-borne human diseases that is caused by the plasmodium parasite. Anopheles mosquitoes are the vector that contains the plasmodium parasite sporozoites. There are 5 most common Plasmodium parasite species that can cause human infection. Those are Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium falciparum, and Plasmodium knowlesi. In 2019, there were about 229 million cases of malaria worldwide. Africa is the most affected country of malaria. The spread and distribution of vector-borne diseases are greatly affected by environmental and climatic factors. Climatic factors especially temperature, humidity and rainfall, affect the ability of malaria parasites and Anopheles vectors to exist long enough to spread disease. An epidemic of malaria occurs when climate and other conditions suddenly favor the spread of malaria in areas where people have little or no immunity to malaria. In China, a sweet sagewort plant known as Qinghai (Latin Artemisia annua) was used to treat malaria as early as the 2nd century BC. Later, Different antimalarial drugs like quinolines, antifolates, and Artemisinin-combination therapies (ACTs) are used to treat malaria. Recently, The World Health Organization (WHO) recommends that children in Sub-Saharan Africa and other places with moderate to high P. falciparum malaria transmission get the RTS,S/AS01 (RTS,S) malaria vaccine. The proposal is based on the outcomes of a trial program that has served over 800,000 children in Ghana, Kenya, and Malawi since 2019.en_US
dc.description.statementofresponsibilitySanjida Sultana Ritu
dc.description.statementofresponsibilityAlaya Ferdous Dihan
dc.format.extent21 pages
dc.language.isoenen_US
dc.publisherBrac Universityen_US
dc.rightsBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectMalariaen_US
dc.subjectAnophelesen_US
dc.subjectPlasmodiumen_US
dc.subjectTemperatureen_US
dc.subjectTransmissionen_US
dc.subjectAntimalarial drugsen_US
dc.subjectMalaria vaccineen_US
dc.subject.lcshMalaria--Chemotherapy
dc.subject.lcshMalaria--Diagnosis
dc.titleMalaria: transmission, diagnosis and treatment: A Reviewen_US
dc.typeThesisen_US
dc.contributor.departmentDepartment of Mathematics and Natural Sciences, Brac University
dc.description.degreeB. Microbiology


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record